Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8299717 | 0.87 | CHRM2 (0.44) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL1721601 | 0.82 | CHRM2 (0.41) | CHRM2CHRM1CHRM3PREPHDAC1 | |
| SCHEMBL1722273 | 0.82 | CHRM2 (0.41) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL1723133 | 0.82 | CHRM2 (0.41) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL10064461 | 0.81 | CHRM2 (0.39) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL1721264 | 0.81 | GPR119 (0.48) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL17075349 | 0.80 | GPR119 (0.43) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 | |
| SCHEMBL15006984 | 0.79 | GPR119 (0.38) | CHRM2CHRM1CHRM3HDAC1GPR119 | |
| SCHEMBL10139275 | 0.79 | HCRTR1 (0.42) | CHRM2CHRM1CHRM3HDAC1GPR119 | |
| Iodide SCHEMBL17075351 | 0.79 | EIF2AK4 (0.39) | CHRM2CHRM1CHRM3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9284322-B2 | Nicotinic receptor compounds | RESEARCH TRIANGLE INSTITUTE (US) | 2016-03-15 | — | — | US | disclosed |
| US-9284322-B2 | Nicotinic receptor compounds | RESEARCH TRIANGLE INSTITUTE (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150307502-A9 | NICOTINIC RECEPTOR COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-29 | — | — | US | disclosed |
| US-20150307502-A9 | NICOTINIC RECEPTOR COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-29 | — | — | US | disclosed |
| US-9150581-B2 | Nicotinic receptor compounds | RESEARCH TRIANGLE INSTITUTE (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150581-B2 | Nicotinic receptor compounds | RESEARCH TRIANGLE INSTITUTE (US) | 2015-10-06 | — | — | US | disclosed |
| US-20150152119-A1 | NICOTINIC RECEPTOR COMPOUNDS | RES TRIANGLE INST (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152119-A1 | NICOTINIC RECEPTOR COMPOUNDS | RES TRIANGLE INST (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150152119-A1 | NICOTINIC RECEPTOR COMPOUNDS | RES TRIANGLE INST (US) | 2015-06-04 | — | — | US | disclosed |
| US-8981102-B2 | Nicotinic receptor compounds | RESEARCH TRIANGLE INSTITUTE (US) | 2015-03-17 | — | — | US | disclosed |
| WO-2012024615-A1 | NICOTINIC RECEPTOR COMPOUNDS | RESEARCH TRIANGLE INSTITUTE (US) | 2012-02-23 | — | — | WO | disclosed |
| EP-2404923-A1 | 7-azabicyclo[2.2.1]heptane derivatives useful for promoting smoking cessation | RESEARCH TRIANGLE INSTITUTE (US) | 2012-01-11 | — | — | EP | disclosed |
| US-20090318490-A1 | COMPOUNDS AND METHODS FOR PROMOTING SMOKING CESSATION | RESEARCH TRIANGLE INSITUTE (US) | 2009-12-24 | — | — | US | disclosed |
| US-7615567-B2 | Compounds and methods for promoting smoking cessation | RESEARCH TRIANGLE INSTITUTE (US) | 2009-11-10 | — | — | US | disclosed |
| US-20060069111-A1 | Compounds and methods for promoting smoking cessation | RESEARCH TRIANGLE INSITUTE (US) | 2006-03-30 | — | — | US | disclosed |
| EP-1351684-A4 | COMPOUNDS AND METHODS FOR PROMOTING SMOKING CESSATION | RES TRIANGLE INST (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1351684-A2 | COMPOUNDS AND METHODS FOR PROMOTING SMOKING CESSATION | Research Triangle Institute (US) | 2003-10-15 | — | — | EP | disclosed |
| US-20030176434-A1 | Compounds and methods for promoting smoking cessation | RESEARCH TRIANGLE INSITUTE | 2003-09-18 | — | — | US | disclosed |
| US-6538010-B1 | Compounds may be used to treat a variety of other conditions and disease states and reagents for preventing smoking addiction. The present invention also relates to methods and reagents for treating nicotine addiction. | RESEARCH TRIANGLE INSTITUTE | 2003-03-25 | — | — | US | disclosed |
| WO-2002037927-A2 | COMPOUNDS AND METHODS FOR PROMOTING SMOKING CESSATION | RESEARCH TRIANGLE INSTITUTE (US) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069111-A1 | Compounds and methods for promoting smoking cessation | BHMT2, CBS, NNMT | CHRM2 420/4885CHRM1 711/4885CHRM3 522/4885 |
| US-20150307502-A9 | NICOTINIC RECEPTOR COMPOUNDS | CHRNB4, CHRNA4, CHRNB2 | CHRM2 28/4885CHRM1 32/4885CHRM3 27/4885 |
| US-20090318490-A1 | COMPOUNDS AND METHODS FOR PROMOTING SMOKING CESSATION | BHMT2, CBS, NNMT | CHRM2 420/4885CHRM1 711/4885CHRM3 522/4885 |
| US-20030176434-A1 | Compounds and methods for promoting smoking cessation | BHMT2, CBS, NNMT | CHRM2 420/4885CHRM1 711/4885CHRM3 522/4885 |
| US-20150152119-A1 | NICOTINIC RECEPTOR COMPOUNDS | CHRNG, CHRNA7, CHRNA2 | CHRM2 19/4885CHRM1 23/4885CHRM3 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.